Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Pharmacol Sci
2008 Nov 01;1083:301-7. doi: 10.1254/jphs.08102fp.
Show Gene links
Show Anatomy links
Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K, Niwa R, Morishima M, Honjo H, Sanguinetti MC.
???displayArticle.abstract???
Block of cardiac hERG K+ channels by the antihistamine terfenadine and the prokinetic agent cisapride is associated with prolonged ventricular repolarization and an increased risk of ventricular arrhythmia. Here, we used a site-directed mutagenesis approach to determine the molecular determinants of hERG block by terfenadine and cisapride. Wild-type and mutant hERG channels were heterologously expressed in Xenopus laevis oocytes and characterized by measuring whole cell currents with two-microelectrode voltage clamp techniques. Mutation of T623, S624, Y652, or F656 to Ala reduced channel sensitivity to block by terfenadine. The same mutations reduced sensitivity to cisapride. These data confirm our previous findings that polar residues (T623, S624) located near the base of the pore helix and aromatic residues (Y652, F656) located in the S6 domain are key molecular determinants of the hERG drug binding site. Unlike methanesulfonanilides (dofetilide, MK-499, E-4031, ibutilide) or clofilium, mutation of V625, G648, or V659 did not alter the sensitivity of hERG channels to terfenadine or cisapride. As previously proposed by molecular modeling studies (Farid R, et al. Bioorg Med Chem. 2006;14:3160-3173), our findings suggest that different drugs can adopt distinct modes of binding to the central cavity of hERG.
Armstrong,
Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons.
1971, Pubmed
Armstrong,
Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons.
1971,
Pubmed Chiu,
Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels.
2004,
Pubmed Curran,
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.
1995,
Pubmed Diaz,
The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
2004,
Pubmed Farid,
New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies.
2006,
Pubmed Fernandez,
Physicochemical features of the HERG channel drug binding site.
2004,
Pubmed
,
Xenbase Ficker,
Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
2001,
Pubmed
,
Xenbase Finlayson,
[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.
2001,
Pubmed Guo,
Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
2006,
Pubmed Heginbotham,
Mutations in the K+ channel signature sequence.
1994,
Pubmed
,
Xenbase Kamiya,
Molecular determinants of HERG channel block.
2006,
Pubmed
,
Xenbase Kemp,
Antihistamines--is there anything safe to prescribe?
1992,
Pubmed Lees-Miller,
Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites.
2000,
Pubmed
,
Xenbase Milnes,
Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.
2003,
Pubmed Mitcheson,
Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.
2000,
Pubmed
,
Xenbase Mitcheson,
A structural basis for drug-induced long QT syndrome.
2000,
Pubmed
,
Xenbase Paul,
Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
2001,
Pubmed Perry,
Structural determinants of HERG channel block by clofilium and ibutilide.
2004,
Pubmed
,
Xenbase Pratt,
Cardiovascular safety of fexofenadine HCl.
1999,
Pubmed Pratt,
Cardiovascular safety of fexofenadine HCl.
1999,
Pubmed Rajamani,
Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block.
2002,
Pubmed Ridley,
High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.
2004,
Pubmed Ridley,
Lidoflazine is a high affinity blocker of the HERG K(+)channel.
2004,
Pubmed Roy,
HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine.
1996,
Pubmed
,
Xenbase Sánchez-Chapula,
Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
2004,
Pubmed
,
Xenbase Sánchez-Chapula,
Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block.
2002,
Pubmed
,
Xenbase Sanguinetti,
Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.
1990,
Pubmed Sanguinetti,
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
1995,
Pubmed
,
Xenbase Sarkar,
The "megaprimer" method of site-directed mutagenesis.
1990,
Pubmed Stork,
State dependent dissociation of HERG channel inhibitors.
2007,
Pubmed
,
Xenbase Stühmer,
Electrophysiological recording from Xenopus oocytes.
1992,
Pubmed
,
Xenbase Wang,
Modulation of HERG affinity for E-4031 by [K+]o and C-type inactivation.
1997,
Pubmed
,
Xenbase Witchel,
The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
2004,
Pubmed
,
Xenbase
